Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herombopag + immunosuppressive therapy vs immunosuppressive therapy in first-line treatment of severe aplastic anemia in children
ChiCTR2200057675Phase 4Not yet recruiting
- Sponsor
- Capital Medical University
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of hetrombopag in aplastic anemia (2 arms), sponsored by Capital Medical University. Primary endpoint: Complete response rate at 6 months. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
hetrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on ChiCTR2200057675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057675.